Acute pulmonary embolism;Akut pulmoner emboli

Anadolu Kardiyoloji Dergisi

Volumn 5, Issue 3, 2005, Pages 221-226

  Okyay, Kaan ^a,b   Cemri, Mustafa ^a   Çengel, Atiye ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; D DIMER; FIBRINOLYTIC AGENT; FONDAPARINUX; HEART ENZYME; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; STREPTOKINASE; WARFARIN; XIMELAGATRAN;

ACUTE DISEASE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; INFERIOR CAVA VEIN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; NUCLEAR MAGNETIC RESONANCE IMAGING; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; EMBOLECTOMY; HEMODYNAMIC PROCESSES; HUMANS; PULMONARY EMBOLISM; PULMONARY GAS EXCHANGE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 24744434010     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Goldhaber SZ, Visani L, De Rosa M,. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet 1999;353: 1386-9
2. Giuntini C, Di Ricco G, Marini C, Malillo E, Palla A. Pulmonary embolism: epidemiology. Chest 1995;107 (1Suppl.): 3S-9S.
3. Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Ann Intern Med 2003; 20: 21-4.
4. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271: 223-5.
5. Task force on pulmonary embolism, European Society of Cardiology. Task force report. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000;21: 1301-36.
6. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.
7. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis Circulation 2003; 108: 2726-9.
8. Timuralp B. Venöz trombüs ve pulmoner tromboembolizm etyopatogenezi-kardiyovasküler sistemde patofizyolojik deǧişiklikler. Ana Kardiyol Derg 2001; 1: 48-52.
9. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-5.
10. Palla A, Petruzzelli S, Donnamaria V, Giuntini C. The role of suspicion in the diagnosis of pulmonary embolism. Chest 1995; 107 (1 Suppl): 21S-24S.
11. Worsley DF, Alavi A, Aronchick JM et al. Chest radiographic findings in patients with acute pulmonary embolism: observations from the PIOPED Study. Radiology 1993; 189: 133-6.
12. van Strijen MJ, de Monye W, Schiereck J, et al. For the Advances in New Technologies Evaluating the Localisation of Pulmonary Embolism Study Group. Single detector helical computed tomography as the primary diagnostic test in suspected pulmanary embolism: a multicenter clinical management study of 510 patients. Ann Intern Med 2003; 138: 307-14.
13. Schoepf UJ, Costello P. CT angiography for diagnosis of pulmonary embolism: state of the art. Radiology 2004; 230: 329-37.
14. Gupta A, Frazer CK, Ferguson JM, et al. Acute pulmonary embolism: diagnosis with MR angiography. Radiology 1999; 210: 353-9.
15. Chan TC, Vilke GM, Pollack M, Brady WJ. Electrocardiographic manifestations: pulmonary embolism. J Emerg Med 2001; 21: 263-70.
16. Ferrari E, Imbert A, Chevalier T et al. The ECG in pulmonary embolism. Predictive value of negative T waves in precordial leads - 80 case reports. Chest 1997; 113: 537-43.
17. Kucher N, Walpoth N, Wustmann K, Noveanu M, Gertsch M. QR in V1 - an ECG sign associated with right ventricular strain and adverse clinical outcome in pulmonary embolism. Eur Heart J 2003; 24: 1113-9.
18. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817-22.
19. Mansencal N, Joseph T, Vieillard-Baron A, et al. Comparison of different echocardio- graphic indexes secondary to right ventricular obstruction in acute pulmonary embolism. Am J Cardiol 2003; 92: 116-9.
20. Goldhaber SZ. Echocardiography in the management of pulmonary embolism. Ann Intern Med 2002;136: 691-700.
21. Bova C, Greco F, Misuraca G, et al. Diagnostic utility of echocardiography in patients with suspected pulmonary embolism. Am J Emerg Med 2003; 21: 180-3.
22. Dunn KL, Wolf JP, Dorfman DM, et al. Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol 2002; 40: 1475-8.
23. Pruszczyk P, Bochowicz A, Torbicki A, et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003; 123: 1947-52.
24. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145: 821-5.
25. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211-7.
26. Muller-Bardorff M, Weidtmann B, Giannitsis E, Kurowski V, Katus HA. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002; 48: 673-5.
27. Tulevski II, Hirsch A, Sanson BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 2001; 86: 1193-6.
28. Tulevski II, Groenink M, van der Wall EE, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86: 27-30.
29. Shimizu Y, Nagaya N, Satoh T, et al. Serum uric acid level increases in proportion to the severity of pulmonary thromboembolism. Circ J 2002; 66: 571-81.
30. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
31. Breddin HK, Hack-Wunderle V, Nako R, et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.N Engl J Med 2001; 344: 626-31.
32. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004; 140: 175-83.
33. Arcasoy SM, Vachani A. Local and systemic thrombolytic therapy for acute venous thromboembolism. Clin Chest Med 2003; 24: 73-91.
34. Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995;107 (1 Suppl): S45-S51.
35. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. Circulation 2003; 108: 2834-8.
36. Goldhaber SZ, Haire WD, Feldstein M, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-11.
37. Konstantinides S,Geibel A, Heusel G, Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-50.
38. Liu P, Meneveau N, Schiele F, Bassan JP. Predictors of long-term clinical outcome of patients with acute massive pulmonary embolism after thrombolytic therapy. Chin Med J (Engl) 2003; 116: 503-9.
39. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338: 409-15.
40. Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105: 1416-9.
41. Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg. 2004; 77: 819-23.
42. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-8.
43. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104: 2311-7.
44. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
45. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
46. Schulman S, Waehlander K, Lundstrom T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl Med. 2003; 349:1713-21.
47. Eriksson H, Wahlander K, Gustafsson D, et al. THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-7.
48. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137: 648-55.
49. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002; 359; 1710-1.
50. Buller HR, Davidson BL, Decousus H, et al.; MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.